Allosteric theory: taking therapeutic advantage of the malleable nature of GPCRs.
about
In vitro pharmacological characterization of RXFP3 allosterism: an example of probe dependencyLigand-induced modulation of the free-energy landscape of G protein-coupled receptors explored by adaptive biasing techniquesUnderstanding the role of prostaglandin E2 in regulating human platelet activity in health and diseaseExploring a role for heteromerization in GPCR signalling specificity.Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations.Melanotropins as drugs for the treatment of obesity and other feeding disorders: potential and problems.Membrane modulates affinity for calcium ion to create an apparent cooperative binding response by annexin a5Design of peptide and peptidomimetic ligands with novel pharmacological activity profiles.On the expanding terminology in the GPCR field: the meaning of receptor mosaics and receptor heteromers.Conformational selection or induced fit? 50 years of debate resolved.KK-92A, a novel GABAB receptor positive allosteric modulator, attenuates nicotine self-administration and cue-induced nicotine seeking in rats.Population Pharmacokinetics and Pharmacodynamics of the Calcimimetic Etelcalcetide in Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis.Screening for GPCR Ligands Using Surface Plasmon ResonancePossible new targets for GPCR modulation: allosteric interactions, plasma membrane domains, intercellular transfer and epigenetic mechanisms.Involvement of Allosteric Effect and K Channels in Crosstalk between β₂-Adrenergic and Muscarinic M₂ Receptors in Airway Smooth Muscle
P2860
Q28480533-AF6885B7-88CD-46E8-84CE-7C8800C01C22Q34055218-BF13D6DC-9576-489C-BA82-3F133DAA273AQ34480894-B6F965A1-8452-47C3-B114-CABCEB62194EQ34660378-47D17BBE-0AF1-4C54-B34A-84345EAFDF59Q35182164-039574CD-2BDA-42F2-84C3-5E16A72B3094Q36170863-50117E14-D94D-4BBE-A63B-5F1FAC90A15BQ36903579-79DD1853-FA9A-473C-9C08-DC380C53D0CDQ37365405-2BDAB801-F4DA-4FA6-BF04-95A84E9438F3Q37739478-E9FD3E9B-0686-4A93-99AB-A2130E188FF8Q38363774-C50D5F38-78B6-4047-83D7-5CB288D90130Q38432098-DF77E45B-C902-4400-B086-061B3B2F0D42Q39379162-432FDC74-856C-427D-BCD7-1251E0EC604EQ42141178-3471B99F-75A7-4857-B0A1-0861D05C1583Q46065953-127E2EA2-9190-4F6A-80A4-CC50B9301C66Q57095751-65410394-0D87-4119-827D-F4FC701258F3
P2860
Allosteric theory: taking therapeutic advantage of the malleable nature of GPCRs.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Allosteric theory: taking therapeutic advantage of the malleable nature of GPCRs.
@en
Allosteric theory: taking therapeutic advantage of the malleable nature of GPCRs.
@nl
type
label
Allosteric theory: taking therapeutic advantage of the malleable nature of GPCRs.
@en
Allosteric theory: taking therapeutic advantage of the malleable nature of GPCRs.
@nl
prefLabel
Allosteric theory: taking therapeutic advantage of the malleable nature of GPCRs.
@en
Allosteric theory: taking therapeutic advantage of the malleable nature of GPCRs.
@nl
P2860
P1476
Allosteric theory: taking therapeutic advantage of the malleable nature of GPCRs.
@en
P2093
Terry Kenakin
P2860
P304
P356
10.2174/157015907781695973
P577
2007-09-01T00:00:00Z